DO-264

Research use only, not for human use.

DO-264 is an inhibitor of autohydrolase structural domain 12 (ABHD12) (IC50: 11 nM) and an inhibitor of cellular LysoPS degradation that enhances LPS-induced phagocytosis.

DO-264 is a selective and in vivo-active inhibitor of Abhydrolase Domain Containing 12 (ABHD12), with an IC50 of 11 nM.

DO-264 displays an IC50 value of 11 nM (9.6 nM-13 nM). DO-264 blocks lyso-PS hydrolysis activities of recombinant mouse and human ABHD12 in transfected HEK293T cell lysates (DO-264 IC50 values of ~30 and 90 nM against mouse and human ABHD12, respectively) and the ABHD12-dependent lyso-PS lipase activity of membrane lysates from mouse brain (IC50=2.8 nM, 2.4 nM-3.3 nM) and human THP-1 cells (IC50= 8.6 nM, 6.3 nM-12 nM).

Mice treated with DO-264 display dose-dependent increases in brain lyso-PS and 20:4 PS content that are qualitatively similar to the changes observed in ABHD12–/– mice. DO-264-treated mice, however, show minimal impairment in auditory function following four weeks of drug exposure. Both ABHD12–/– and DO-264-treated mice display exacerbated immunopathology following infection with the lymphocytic choriomeningitis virus (LCMV) clone 13, resulting in severe inflammatory lung damage, heightened chemokine production, and, in some cases, death.

——

Others

Other Targets

Others

——

——

2301866-59-9

558.4

C23H20Cl2F3N5O2S

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (179.08 mM )

FC(F)(F)Oc1ccc(Oc2ccnc(N3CCC(CC3)NC(=S)Nc3cccnc3)c2Cl)c(Cl)c1

——

(-20℃)

With Ice Pack

≥ 2 years